Given that genetic REV-ERBα loss of function results in cognitive impairment [9], we sought to determine if pharmacological REV-ERB gain of function may improve cognitive function in a model of cognitive impairment and in particular AD. The gene discussed is NR1D1; the disease is Cognitive impairment.